Ignite Creation Date:
2025-12-25 @ 5:18 AM
Ignite Modification Date:
2026-02-25 @ 4:05 AM
Study NCT ID:
NCT02090127
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2015-07-29
First Post:
2014-03-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Sponsor:
AVEO Pharmaceuticals, Inc.
Organization:
Study Overview
Official Title:
Expanded Access Protocol to Provide Ficlatuzumab to P05538 Patient 0001-000412
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2015-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Detailed Description:
This treatment protocol will serve as a mechanism to continue to provide ficlatuzumab to patient 0001-000412, who was previously enrolled under protocol P05538 and whom the investigator believes is deriving clinical benefit from ficlatuzumab treatment.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: